Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.~* Active SLE disease.~* Autoantibody-positive.~* Have antibodies with titers \>1.0 microgram (mcg)/mL to no more than 9 of the 23 serotypes present in the pneumococcal vaccine.~* Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures.~Key Exclusion Criteria:~* Pregnant or nursing.~* Have received any prior treatment with belimumab.~* Have received a live vaccine within the past 30 days.~* Have received a pneumococcal vaccination with the past 5 years.~* Have a history of severe allergic reaction to a vaccine, contrast agents (such as those used for x-rays and CT scans), or biological medicines.~* Have required management of an infection or have had infections that keep coming back within the past 60 days.~* Hepatitis B: Serologic evidence of Hepatitis B (HB) infection based on the results of testing for HB surface antigen (HBsAg) and anti-HB core antibody (anti-HBc):~  * Subjects positive for HBsAg are excluded.~ * Subjects negative for HBsAg but positive for anti-HBc, regardless of anti-HBs antibody status, are excluded.~* Hepatitis C: Positive test for Hepatitis C antibody.~* Known human immunodeficiency virus (HIV) infection.~* Have current drug or alcohol abuse or dependence.~* Have a Grade 3/4 immunoglobulin (Ig)G deficiency (IgG level \<400 milligrams \[mg\]/ deciliter \[dL\]) or IgA deficiency (IgA level \<10 mg/dL).~* Subjects who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or suicidal ideation with some intent to act in the last 2 months or who in the investigator's judgment, pose a significant suicide risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belimumab plus Early Vaccination (Type: EXPERIMENTAL): Belimumab plus Early Vaccination
- Belimumab plus Late Vaccination (Type: EXPERIMENTAL): Belimumab plus Late Vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).